HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Survival Of The Fittest: IQVIA’s Seven Rules For Post-COVID Success

Executive Summary

IQVIA Consumer Health sets out in a new report seven priorities for post-lockdown business strategy to help consumer health firms emerge out of the coronavirus pandemic stronger than ever.

You may also be interested in...

Coronavirus Pandemic Accelerating Shift To Digitally-Enabled Innovation

Virtual trials could be the answer to limitations placed on innovation by the coronavirus pandemic and help companies formulate new health claims relevant to a new generation of consumers, argued IQVIA Consumer Health during a recent webinar. 

The New Normal? How COVID-19 Has Impacted Europe's Consumer Health Market

IQVIA Consumer Health's analysis of the impact of the coronavirus pandemic on Europe's OTC market based on the latest sales data. 

Very Few OTC Launches ‘Excellent', Claims IQVIA Consumer Health

Most OTC product launches failed to live up to expectations, according to new research by IQVIA Consumer Health. IQVIA's Andy Tisman offers some principles for OTC firms to follow to achieve launch 'excellence'. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts